Systemic Mastocytosis Mayhem Webcast 2

CE / CME

Systemic Mastocytosis Mayhem: Clinical Data on New and Emerging Therapies

Nurse Practitioners/Nurses: 0.50 Nursing contact hours, includes 0.50 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Released: May 16, 2025

Expiration: May 15, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Your patient has indolent SM with KIT D816V mutation. For 6 mo, a combination of antimediator therapies improved itching and diarrhea, but now symptoms are worsening, so you and the patient are considering addition of the selective KIT inhibitor avapritinib.

Based on the PIONEER trial, which statement would be correct when discussing avapritinib symptom benefits with your patient?